51012-31-8

Basic information

• Product Name: 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci
• Synonyms: 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci;2-(4-chlorophenylsulfonamido)benzoic acid
• CAS NO: 51012-31-8
• Molecular Formula: C₁₃H₁₀ClNO₄S
• Molecular Weight: 311.744
• Mol File: 51012-31-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 507.7°Cat760mmHg
• Flash Point: 260.8°C
• Appearance: /
• Density: 1.535g/cm³
• Vapor Pressure: 9.22E-11mmHg at 25°C
• Refractive Index: 1.66
• CAS DataBase Reference: 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci(51012-31-8)
• EPA Substance Registry System: 2-(((4-chlorophenyl)sulfonyl)amino)-benzoicaci(51012-31-8)

Safety Data

• Hazardous Substances Data: 51012-31-8(Hazardous Substances Data)

Usage

Specific content

Different sources of media describe the Specific content of 51012-31-8 differently. You can refer to the following data:
1. The chemical compound's full name, which is used for identification and classification purposes.
2. The colloquial name for the compound, which is more widely recognized and easier to remember.
3. The category of drugs to which the compound belongs, indicating its primary function and mechanism of action.
4. The primary medical use of the compound, which is to alleviate symptoms of pain and inflammation in various conditions.
5. The way in which the compound exerts its therapeutic effect, by reducing the levels of prostaglandins, which are responsible for causing pain and inflammation.
6. Withdrawal from the market
6. The fact that zomepirac is no longer available for medical use due to safety concerns.
7. The severe side effects that led to the withdrawal of zomepirac from the market, highlighting the potential risks associated with its use.
8. A warning to exercise caution when dealing with the compound, as it may pose significant health hazards.

Classification

Non-steroidal anti-inflammatory drug (NSAID)

Purpose

Treatment of pain and inflammation

Mechanism of action

Inhibition of prostaglandin production

Associated adverse effects

Kidney failure and serious health complications

Precautions

Handle with caution due to potential health risks

InChI:InChI=1/C13H10ClNO4S/c14-9-5-7-10(8-6-9)20(18,19)15-12-4-2-1-3-11(12)13(16)17/h1-8,15H,(H,16,17)

Upstream product

• 200633-37-0 N-(2-(methoxycarbonyl)phenyl)-4-chlorobenzenesulfonamide 
• 118-92-3 anthranilic acid 
• 98-60-2 4-chlorobenzenesulfonyl chloride 

Downstream Products

• 2894-51-1 2-amino-4'-chlorobenzophenone 

Relevant articles and documents

INHIBITING OTUB1

The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of OTUB1. The compounds are further useful in the inhibition of OTUB1 and the treatment of diseases or disorders associated with the inhibition of OTUB

Deoxygenative Arylation of Carboxylic Acids by Aryl Migration

An unprecedented deoxygenative arylation of aromatic carboxylic acids has been achieved, allowing the construction of an enhanced library of unsymmetrical diaryl ketones. The synergistic photoredox catalysis and phosphoranyl radical chemistry allows for precise cleavage of a stronger C?O bond and formation of a weaker C?C bond by 1,5-aryl migration under mild reaction conditions. This new protocol is independent of substrate redox-potential, electronic, and substituent effects. It affords a general and promising access to 60 examples of synthetically versatile o-amino and o-hydroxy diaryl ketones under redox-neutral conditions. Furthermore, it also brings one concise route to the total synthesis of quinolone alkaloid, (±)-yaequinolone A2, and a viridicatin derivative in satisfying yields.

Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors

The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.